TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Completion of recommended laboratory monitoring
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Menstrual pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of collar usage
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of Rickets as Measured by Rickets Severity Score (RSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of hospitalization for HSCT
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cost incorporation of a physiotherapist into the team
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number, characteristics and incidence of immediate complications of HSCT
Endpoint domain: Adverse events/effects
Primary endpoint: Antimicrobials used in infectious complications and chemotherapy conditioning
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ischemia-modified albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hearing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving Disease Control (Non-progressive Disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of BIBW 2992
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life measured by Barthel index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measured by EQ5-D scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neural activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of Anastomotic Leak
Endpoint domain: Adverse events/effects
Primary endpoint: Brochiolitis Obliterans Syndrome (BOS) -free survival
Endpoint domain: Mortality/survival
Primary endpoint: reduction in next-day spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no increase in next-day somnolence/fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Subjective Symptom Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bioavailability of sublingual ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma drug concentration-time curve (AUC0-last) of CKD-519
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of CKD-519
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neck contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior hairline placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scars placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chronic post-thoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20 % Change in iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: normalization of 25VD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in trust in mother
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of NT-proBNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biological Age Prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ascites Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydrothorax Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of infants achieving Hib IgG concentrations ≥0.15 µg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of infants achieving MenC SBA titres ≥8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of infants achieving Hib IgG concentrations ≥1.00 µg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of infants achieving MenC SBA titres ≥128
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hib IgG GMCs at one month after primary immunisation schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative intravenous morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total grams of ad libitum meal consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to the first relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Toxicity Evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of circulating Th1 lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: embryos survival after thawing
Endpoint domain: Mortality/survival
Primary endpoint: implantation in the uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of sessions of complementary techniques
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prostate Specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability in healthy volunteers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability in mild asthmatics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of Serological Markers for Hepatitis B Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fluid Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Unpleasantness of Breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in bodily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevention of acid rebound phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of moderate, severe and life threatening adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proprioception testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Urinary Flow Rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postvoid Residual Urine (PVRU) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: General safety endpoints
Endpoint domain: Adverse events/effects
Primary endpoint: Level of the inflammatory receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of adolescents with HIV-RNA <50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ADAS-Cog 11 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in ADCS-CGIC scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-Operative Unstable Angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-Operative Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in c-Flow3310-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients completing chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initial presentation of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mini-Mental Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daily crying frequency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Echocardiography acquisition score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Displacement of the echocardiography probe with respect to the 2D reference acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) - Percentage of Participants With an Event
Endpoint domain: Mortality/survival
Primary endpoint: Progression-Free Survival - Time to Event
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Progression Free at 12 and 24 Months
Endpoint domain: Mortality/survival
Primary endpoint: Decisional Conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evacuation fraction (%) of radioactive material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of retrograde movement of radioactive material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hirschsprung and Anorectal Malformations Quality of life Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cmax of GBT440
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tmax of GBT440
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC of GBT440
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: T1/2 of GBT440
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement by at Least 2 Points in Histology (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Anatomic occlusion of the aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Orthodontic Tooth Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-hydroxyvitamin D3 (25-OHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Culture results of respiratory specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gene expression of RAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Suboptimal Estrogen Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of passively detected malaria cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants experiencing discomfort related to wearing the appliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion time of the appliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HPV-16/18 Antibody Titers in Serum at Years 5, 6 and 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-16/18 Antibody Titers in Serum at Years 8, 9 and 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Years 5, 6 and 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Years 8, 9 and 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Itch-Numeric Rating Scale (I-NRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition from weight management
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Signal intensity of Magnetic Resonance Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients who are a clinical success at Day 14 postoperative visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading inflammatory changes in the rotator interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nigrostriatal uptake of [18F]FDOPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postprandial Blood Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in Overall Lifting and Tightening of Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absorptive Clearance Rate After Isotonic Saline Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absorptive Clearance Rate After Hypertonic Saline Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mucociliary Clearance Rate After Isotonic Saline Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mucociliary Clearance Rate After Hypertonic Saline Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PCM Clotting Time (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot Formation Time (CFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean (%CV) area under the plasma concentration time curve from 0 to 24 hours (AUC0-24) of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean (%CV) area under the plasma concentration time curve from 0 to 24 hours (AUC0-24) of tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean (%CV) maximum plasma concentration (Cmax) of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean (%CV) maximum plasma concentration (Cmax) of tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of core symptoms of stroke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Direct EMS call by stroke patients/bystanders
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of fractures setting and osteotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: provoked aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of Serum Total IgG and IgG Subclasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of Specific Antibodies Against Defined Infectious Agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Solicited Local Symptoms, Overall
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Unsolicited Adverse Events (AEs), Overall
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Haematological Laboratory Abnormalities, Overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anatomical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inappropriate line crossings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: highest tolerable dose of CP-675,206
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration [Cmax] of CKD-519
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total average nutrition supplement scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of allogenic blood units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Psychophysical Assessment of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS of Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS of Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ECM assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in function as measured by the sit to stand 30 seconds test (STS30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-HBs titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic Cost of Transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adjusted Mean Beck Depression Inventory-II Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Change Scores on Beck Depression Inventory-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Study Completers With Remitted Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of Aspiration Events on Videofluoroscopic Swallow Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perceived Swallowing Difficulty on Swallowing Disturbance Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stand-Walk-Sit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time sedentary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful first cannulation attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival with own liver at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Overall rate of endoscopic bile duct stone clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants with Detrusor underactivity or Bladder outlet obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: durable pain palliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of HEP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive predictive value of HEP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Negative predictive value of HEP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Interface pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mother-to-child transmission of HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment Related Non-hematologic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with biochemically confirmed smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who self-report smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preferred side of the scar
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Total Ventilation Defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of new ischemic brain injury detectable on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: aseptic loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Drive for Thinness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Body Dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inspection of hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes